Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

Is diabetes mellitus a wrongdoer to COVID-19 severity?

Sanjib Sarkar\textsuperscript{a, b}, Dibyendu Das\textsuperscript{a, b}, Sawlang Borsingh Wann\textsuperscript{a, b}, Jatin Kalita\textsuperscript{b, c, *}, Prasenjit Manna\textsuperscript{a, b, *}

\textsuperscript{a} Biotechnology Group, Biological Sciences and Technology Division, CSIR-North East Institute of Science and Technology, Jorhat 785006, Assam, India
\textsuperscript{b} Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
\textsuperscript{c} Research Planning and Business Development Division, CSIR-North East Institute of Science and Technology, Jorhat 785006, Assam, India

\textbf{Article Info}

\textbf{Article history:}
Received 29 December 2020
Received in revised form
25 May 2021
Accepted 29 June 2021
Available online 1 July 2021

\textbf{Keywords:}
COVID-19
Diabetes Mellitus

\textbf{Abstract}

The coronavirus disease 19 (COVID-19) has turned out to be a pandemic in short period of time due to the high transmissibility of its causative agent, severe acute respiratory syndrome coronavirus 2. Various reports have suggested the promising link between overexpression of angiotensin converting enzyme 2 (ACE2) and COVID-19 pathogenesis. The severity of COVID-19 pathophysiology is greatly depended on several comorbidities, like hypertension, diabetes mellitus (DM), respiratory and cardiovascular disease, out of which DM has emerged as a major risk factor. The current review focuses on the link among the expression of ACE2, use of ACE inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), and risk of COVID-19 pathogenesis in DM. The review also emphasizes on synergistic detrimental effect of DM and COVID-19 on the immune system in provoking uncontrolled cytokine storm which eventually leads to lethal consequences. Finally, several

Abbreviations: ACE, angiotensin converting enzyme; ACEI, angiotensin converting enzyme inhibitor; AGEs, advanced glycation end products; ARDS, acute respiratory distress syndrome, CF, cystic fibrosis; Ang (1–7), angiotensin (1–7); Ang II, angiotensin II; ARB, angiotensin II type 1 receptor blocker; AT\textsubscript{1}R, angiotensin type 1 receptor; CCL, chemokine (C-C motif) ligand; CDC, Centers for Disease Control and Prevention; COVID-19, coronavirus disease 19; CRP, C-reactive protein; CXCL10, C-X-C motif chemokine 10; DAMPs, damage-associated molecular patterns; DM, diabetes mellitus; DPP4, dipeptidyl peptidase IV; EG, envelope glycoprotein; GLP-1, free fatty acid glucagon-like peptide-1; GM-CSF, granulocyte–macrophage colony-stimulating factor; HAG, heamagglutinin-acetyesterase glycoprotein; HMGB-1, high mobility group box protein 1 (ICU, intensive care unit); IKK\textsubscript{b}, I\textkine kinase \textsubscript{b}; IL, interleukin; INF, interferon; JNK, c-Jun N-terminal kinase; LDL, low density lipoprotein; MAPK, mitogen-activated protein kinase; MasR, Mas receptor; MCP-1, monocyte chemoattractant protein-1; MERS, Middle Eastern respiratory syndrome; MERS-CoV, Middle Eastern respiratory syndrome coronavirus; MG, membrane glycoprotein; NCF, nucleocapsid phosphoprotein; NE, neutrophil elastase; NETs, neutrophil extracellular traps; NF-κ\textkine, nuclear factor-κ\textkine; PAD4, peptidylarginine deiminase type 4; PAMPs, pathogen-associated molecular patterns; PKC, Protein kinase C; PLC, phospholipase C; RAGE, receptor for advanced glycation end products; RAS, renin angiotensin system; SARS, severe acute respiratory syndrome; ROS, reactive oxygen species; SARS-CoV, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SG, spike glycoprotein; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TGR, triglyceride; Th, T helper; TLR, Toll-like receptors; TLR, toll-like receptor; TMPRSS2, transmembrane protease, serine 2; TNF, tumour necrosis factor; Treg, T regulatory; UTI, urinary tract infection

* Corresponding authors at: Research Planning and Business Development Division, CSIR-North East Institute of Science and Technology, Jorhat 785006, Assam, India (J. Kalita); Biotechnology Group, Biological Sciences and Technology Division, CSIR-North East Institute of Science and Technology, Jorhat 785006, Assam, India (P. Manna).
E-mail addresses: kalitajk74@gmail.com (J. Kalita), pmanna2012@gmail.com (P. Manna).

https://doi.org/10.1016/j.diabres.2021.108936
0168-8227/© 2021 Elsevier B.V. All rights reserved.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, single stranded, positive sense RNA bearing novel coronavirus of genus *Batacoronavirus*, family *Coronaviridae* which also involves other two coronaviruses such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle Eastern respiratory syndrome coronavirus (MERS-CoV). An outbreak of severe acute respiratory syndrome (SARS) which was triggered by SARS-CoV appeared from mammals such as bat and palm civet [1,2] in southern China in 2002–2003 and killed approximately 800 people. After a decade, MERS-CoV brought about an epidemic of Middle Eastern respiratory syndrome (MERS) in Soudi Arabia and caused 858 deaths [3]. In December 2019, a zoonotic outbreak of coronavirus disease 19 (COVID-19) which is caused by SARS-CoV-2 emerged in Wuhan, Hubei province, China [4-6]. Like, SARS and MERS, COVID-19 is expected as an airborne disease and spreads human to human through microdroplets which are released during exhalation, talking, and coughing [7]. As it spread worldwide rapidly, WHO announced COVID-19 as a pandemic. COVID-19 had been spread across the world, affected more than 100 million people, and caused a fatality more than 2 million individuals as of 1 February 2021 [8]. The high pathogenicity and virulence of SARS-CoV-2 may be gained due to antigenic drift and/or antigenic shift during the transfection of hosts’ cells. The usual indications of COVID-19 are fever, dry cough, tiredness, complication in breathing and sometimes pneumonia and multi-organ failure [9]. The severity of clinical manifestation is escalated with comorbidities of diabetes mellitus (DM), hypertension, cardiovascular diseases, and pulmonary disease.

DM, characterised by higher blood sugar resulting from impaired insulin secretion and/or insulin resistance, is a metabolic disorder which is associated with the higher risk of acquiring infectious diseases [10–12] due to impaired function of immune system [13]. Hyperglycemia and diabetes mellitus have been proved as independent prognosticator of morbidity and fatality in patients with SARS [14] as well as MERS [15]. Likewise, DM has emerged as a major risk factor which increases severe illness and death of patients with COVID-19 [16–18]. Some studies suggest that pre-existing DM is linked with the higher risk of acquiring COVID-19; nonetheless, a meta-analysis has shown that pre-existing DM does not rise the risk of SARS-COV-2 infection [19]. However, the outcome of COVID-19 may be exacerbated due to prior incidence of uncontrolled DM. The present review sheds light on the probable molecular mechanism of severity’s escalation of pathophysiology in COVID-19 patients associated with DM. The review emphasises on the relationship between the expression of virus’ cell surface receptors like ACE2 and TRPRSS2 and the risk of SARS-CoV-2 infection. This review also aims to provide possible molecular mechanisms of abnormal cytokine storm which is generated in COVID-19 patients associated with dysregulation of glucose metabolism and potential therapeutics thereof. In addition, a number of probable therapeutics has been discussed to reduce the elevated risk associated with COVID-19 in subjects with DM.
2. Prevalence of DM comorbidity in COVID-19 patients

The epidemiological and clinical manifestations of patients with COVID-19 have shown that the comorbidities including DM, hypertension, and cardiovascular disease, and other complications are very common in the patients [16,17,20–26]. Among these comorbidities, DM has emerged as a critical risk factor to the COVID-19 patients. A retrospective and multicentre cohort study has reported that 36 (19%) patients showed DM as second highest comorbidity among 191 patients with COVID-19, of whom 17 (31%) patients with DM died due to COVID-19 in hospital [16]. In a clinical investigation of 1099 patients with COVID-19, 173 patients were severely infected who exhibited comorbidities of DM (16.2%), hypertension (23.7%), and cardiovascular disease (5.8%) [17]. A retrospective study of 138 COVID-19 positive patients has demonstrated that 36 severely affected patients had hypertension (58.3%), cardiovascular disease (25.0%), and diabetes mellitus (22.2%) [20]. Another investigation has done on 58 severe COVID-19 patients who suffered from hypertension (37.9%) and diabetes mellitus (13.8%) [21]. The risk of diabetes in respect to poor early outcomes, like requirement of admission to ICU, mechanical ventilation, and death within 14 days after providing critical facilities was studied in 450 COVID-19 hospitalized patients. The study reported significantly higher requirement of ICU (42.1% vs 29.8%), mechanical ventilation and greater proportion of death in patients with diabetes compared to non-diabetes [27]. Surprisingly, the case-fatality rate study of a subsample with 355 patients who died due to SARS-CoV-2 infection reported that 126 (35.5%) patients had diabetes which was found as highest comorbid disease in the sample [28]. In addition, COVID-19 patients with DM showed higher percentage of severe abnormalities [16,17,20–24,26,28–31]. The numbers of COVID-19 patients along with comorbidity of DM are summarized in Table 1.

3. Expression of angiotensin converting enzyme 2 (ACE2) in DM and severity of COVID-19 pathophysiology

The spike glycoproteins (SG) on the surface of SARS-CoV-2 interact with the human ACE2 [38] to enter into cells of lung epithelium, pancreas, kidney, intestine and vascular system (Fig. 2). The viral SG is a trimeric integral membrane protein, and its extracellular domain S1 has a serine protease cleavage site. The SG is activated by humans’ transmembrane protease, serine 2 (TMPRSS2) is allowed to bind to ACE2, permitting the entry of viral genome or entire virus (Fig. 2). TMPRSS2 is a serine protease and widely collocated with ACE2 on various human tissues (Fig. 1) [40].

Ace2, a monocarboxypeptidase, is highly expressed on oral mucosa, respiratory tract, lung, kidney, pancreas, cardiovascular system, intestine, cerebral neuron, and immune cells (Fig. 1) [40–42]. ACE2 converts angiotensin II (Ang II) to angiotensin (1–7) [Ang (1–7)] and maintains a balance between them. Ang (1–7) interacts with Mas receptor (MasR) which facilitates the functions like vasodilation and anti-inflammation which are opposite to the angiotensin type 1 receptor (AT1R) mediated functions done by Ang II [43]. Therefore, the higher expression of ACE2 improves vasodilation and mitigates inflammation and fibrosis of tissues (Fig. 2). The axis of ACE2/Ang (1–7)/MasR counteracts the functions which are accomplished by the ACE/Ang II / AT1R axis in the renin-angiotensin system [44].

Sufficient studies have not been done yet to understand the expression level of ACE2 in individuals with diabetes compared to without diabetes. One cross-sectional investigation identified the reduced expression of ACE2 in both the tubulointerstitium and glomeruli in patients with diabetic kidney disease compared to healthy control [45]. It has been suggested that the expression of ACE2 is decreased in patients with diabetes perhaps due to glycosylation [46]. However,

| Table 1 – COVID-19 patients with comorbidity of diabetes mellitus. |
|-------------------------|-------------------------|-------------------------|
| No. of patients | Comorbidity of diabetes mellitus | Refs |
|-----------------|-------------------------|-------------------------|
| Total | Severe/ICU care/ Non-Survivor | Non-severe/Non-ICU care/Survivor |
| 191 | 36 (19%) | 17 (31%) | 19 (14%) | [16] |
| 1099 | 81 (7%) | 28 (16%) | 53 (6%) | [17] |
| 138 | 14 (10%) | 8 (22%) | 6 (6%) | [20] |
| 140 | 17 (12%) | 8 (14%) | 9 (11%) | [21] |
| 201 | 22 (11%) | 16 (19%) | 6 (5%) | [22] |
| 187 | 28 (15%) | 16 (31%) | 12 (9%) | [23] |
| 1590 | 130 (8%) | 45 (21%) | 85 (6%) | [24] |
| 41 | 8 (19%) | 1 (8%) | 7 (25%) | [25] |
| 52 | 9 (17%) | 7 (22%) | 2 (10%) | [26] |
| 355 | 126 (35%) | 126 (35.5%) | NA | [28] |
| 1561 | 153 (10%) | 122 | 31 | [29] |
| 4103 | 614 (15%) | 176 (27%) | 438 (14%) | [30] |
| 7337 | 952 (13%) | NA | NA | [31] |
| 5700 | 1808 (34%) | NA | NA | [32] |
| 1082 | 235 (21%) | 65 (28%) | NA | [33] |
| 135 | 12 (9%) | 9 (23%) | 3 (3%) | [34] |
| 3481 | 566 (16%) | NA | NA | [35] |
| 19,256 | 3524 (18%) | NA | NA | [36] |
| 377 | 118 (31%) | 45 (40%) | 73 (28%) | [37] |
one observational clinical study reported the elevated protein expression of ACE2 in alveolar tissues and bronchial epithelium of COVID-19 patients with diabetes compared to those without diabetes [47]. On the other hand, administration of renin-angiotensin system (RAS) inhibitors, like lisinopril, an ACE inhibitor (ACEI) and losartan, an angiotensin II type 1 (AT1) receptor blocker (ARB), to mice promoted the increase in cardiac expression of ACE2 by 5 folds and 3 folds, respectively [48]. In addition, another preclinical study has shown that the use of ARBs improve the mRNA or protein expression of ACE2 in tissues of experimental animals [49]. Although, the effect of ACE inhibitors on the expression and activity of ACE2 in experimental animal models are not consistent [50], use of RAS inhibitors seems to increase the expression of ACE2. That is why, a recent speculation has suggested that the patients who had comorbidities like DM, hypertension and cardiovascular disease and were treated with ACEIs and ARBs, are more prone to SARS-CoV-2 infection [51]. However, clinical investigations did not find considerable association between use of ACEIs and ARBs and risk of SARS-CoV-2 infection. According to some case-control studies involving a large number of people, previous treatment with ACEIs and ARBs did not raise the risk of SARS-COV-2 infection [52,53]. It was also assumed that the patients taking either ACEIs or ARBs may rise the expression of ACE2 in pulmonary blood vessels and thereby are at high risk of aggravated consequences of COVID-19 [54]. However, the continuous treatment of these RAS inhibitors among hospitalised COVID-19 patients did not affect the overall outcome of COVID-19 severity in randomised clinical trials [55,56]. In addition, the follow-up evaluation of those COVID-19 patients who participated in continuous and discontinuous ACEIs and ARBs treatment showed no significant difference in COVID-19 severity as well as blood pressure, serum potassium and serum creatinine levels [55]. According to current international society guidelines, the physicians can recommend to continue these drugs for the hospitalised COVID-19 patients if there is no clear medical conflict to continue the treatment.
3.1. Development of transient DM by SARS-CoV-2 infection

A recent in vitro and ex vivo study suggested the confirmed expression of ACE2 on the pancreatic islets particularly on β cells [57]. In other investigations, the expression ACE2 protein was found in pancreatic ductal epithelium, exocrine capillaries, and pericytes; however, no evidence of was found in α and β cells [58,59]. The contradictory results may be obtained due to differences in antibody reactivity level, epitope properties, tissue section preparation, and immunodetection methodology sensitivity [57]. The previous report suggested that the spike glycoprotein of SARS-CoV binds to ACE2 which are situated on the surface of pancreatic islets and damage the islet mass [60]. As a consequence, insulin production is hampered significantly. In addition, the clinical study observed that more than 50% of SARS-CoV infected hospitalised patients developed diabetes. Furthermore, 5% of the patients who recovered from SARS exhibited DM even after 3 years [60]. The COVID-19 patients were newly diagnosed with diabetes mellitus was also amplified in the hospital-admitted COVID-19 patients [62]. As a consequence, the doses of glucose lowering drugs were increased in patients with diabetes after SARS-CoV-2 infection and hospitalization. Among hospitalized COVID-19 individuals who had DM, 29.2% patients who were associated with previous insulin therapy were treated with elevated dose of insulin. Additionally, the new insulin therapy was initiated in 37.5% hospitalized patients who took oral anti-diabetic medicine. Moreover, the insulin dose was also elevated in COVID-19 patients with DM admitted to ICU for managing hyperglycemia [63]. However, the studies were conducted in small sample size and in single centre which warrants additional clinical evidences from multicentre cohorts. Overall, the use of unwanted or elevated dose of insulin to maintain euglycaemia of the COVID-19 patients with DM may be the consequences of more severe stress and inflammatory condition exacerbating insulin resistance.

4. Impairment of immune response in DM and COVID-19

It is not surprising that metabolism and immunity have evolved very closely and are interdependent. Numerous components of immune system are altered in metabolic disease T2DM, and the overt alteration has been seen in adipose tis-
Fig. 3 – Proposed mechanism of pro-inflammatory cytokines and chemokines production in DM. Chronic hyperglycemia facilitates hyperlipidemia and upregulation of AGEs, HMGB-1, and ROS production. Hyperlipidemia promotes the elevation of triglyceride (TGR) and low density lipoprotein (LDL) which increase FFA and oxi-LDL activating membrane bound TLR2/4 of adipocytes and hepatocytes. The upregulation of HMGB-1 triggers the activation of TLR2/4 and RAGE which intern increases the activity of transcription factor NF-$\kappa$B through the rise of IKK$\beta$ (I$\kappa$B kinase $\beta$). AGEs upsurges cellular level of NF-$\kappa$B by interacting RAGE. Hyperglycemia activates PLC and rises DAG which trigger PKC activation resulting in elevation of NADPH oxidase and ROS. NF-$\kappa$B is upregulated in presence of ROS. HMGB-1 and ROS activate MAP kinase and thereby phosphorylate JNK. NF-$\kappa$B and activated JNK lead to increased production of pro-inflammatory cytokines and chemokines.
bidities of DM and other diseases like hypertension, cardiovascular disease in COVID-19 trigger abnormal cytokines storms that lead to uncontrolled function in immune system. As a consequence, the mortality rate of COVID-19 patients associated with DM and/or hyperglycemia is considerably greater than patients without diabetes [75]. The possible mechanism of abnormal cytokine storm which is generated in COVID-19 patients with diabetes has been illustrated in Fig. 4.

SARS-CoV-2 infects the lung epithelium and can cause virus mediated pyroptosis which leads to vascular seepage as reported in COVID-19 patients [76]. Pyroptosis is a highly inflammatory state of programme cell death which is observed in cytopathic virus [77] like SARS-CoV-2, activating subsequent inflammatory responses. As a result of pyroptosis, damaged epithelial cells release pathogen-associated molecular patterns (PAMPs) like viral RNA and damage-associated molecular patterns (DAMPs) such as host DNA, ATP, and ASC oligomers, which are detected by lung epithelial macrophages [67]. Moreover, a wide range of pro-inflammatory mediators such as granulocyte–macrophage colony-stimulating factor (GM-CSF), IL-6, INF-γ, IL-10, monocyte chemoattractant protein-1 (MCP-1) [25], CCL (chemokine (C-C motif) ligand) 2, CCL5 and C-X-C motif chemokine 10 (CXCL10) [78] is secreted into blood of adversely affected COVID-19 patients. Thus, diabetes mellitus causes rapid exacerbation of COVID-19 pathophysiology and often leads to death of comorbid patients.

4.2. Elevation of neutrophil extracellular traps (NETs) in DM and COVID-19

In the sites of infection, neutrophils are recruited at the early onset to destroy pathogens including virus, bacteria and fungi by well-known processes such as oxidative burst and phagocytosis [79]. In addition, neutrophils show another method of
destroying pathogen by formation of neutrophil extracellular traps (NETs), web-like structures of decondensed chromatin and proteins which are expelled from the neutrophils [80]. Several enzymes are associated in NETosis, a cell death process of NET formation. NETosis involves neutrophil elastase (NE), which damages intracellular proteins and promotes nuclear denaturation, peptidylarginine deiminase type 4 (PAD4), which citrullinates histones to induce the decondensation and secretion of chromosomal DNA, and gaseodernin D that creates holes in the neutrophils’ plasma membrane triggering the degradation of the cell boundary and the outburst of DNA and associated components [80]. NETs play a vital role in host defense by killing pathogens; however, the continuous formation of NETs during viral infection [79] facilitates the pathogenesis of several diseases such as inflammatory diseases and some proposed diseases like glomerulonephritis, chronic pulmonary disease, sepsis, and vascular diseases [81]. Thus, NETs act as double-edge swords of innate immunity in an individual [81]. Unfortunately, diabetes mellitus is associated with the exaggerated induction and constitutive NETosis. It has reported that the expression of PAD4 was abnormally high in neutrophils collected from patients with DM [82]. Additionally, the citrullinated histone H3 was elevated in wound, and the healing was delayed in human and mice with diabetes [82]. Moreover, high blood glucose and T2DM can trigger formation of NETs which leads to delay in wound healing process [82]. NETs are also associated several other complications such as acute respiratory distress syndrome (ARDS), cystic fibrosis (CF), excessive thrombosis, and cytokines storm which are very similar in the patients with severe COVID-19 [80]. The mucous secretions, which are common in CF, found in airways of patients with COVID-19. The comorbidity with DM and COVID-19 seems to facilitate the excessive NETosis which may results in thick and viscous mucous in lung alveoli due to increased NE. This deposition of mucous not only impairs ventilation but also allows the colonization pathogenic bacteria [80]. Thus, the combination of two diseases seems to exacerbate the immune-pathophysiology in the patients with DM and COVID-19.

4.3 Abnormal response of T and B lymphocytes in DM and COVID-19

CD4 + T lymphocyte have two major subsets cells, pro-inflammatory cells like T helper (Th) type 1 and Th17 and anti-inflammatory cells like Th2 and Foxp3 + T regulatory (Treg), which maintain an appropriate balance to avoid inflammatory disease in healthy individual [83]. In T2DM, however, number of Th1 and Th17 cells were elevated whereas Treg cells were decreased [83]. Th1 cells that are raised in specifically SARS-CoV and MERS, were observed to secrete some inflammatory factors such as IFN-γ, TNF-α, and IL-2 [84]. Similarly, the COVID-19 individuals exhibited elevated production of IL-2 and IFN-γ [85]. In COVID-19 patients with uncontrolled DM, intensified production of these cytokines by CD4 + T lymphocytes may lead to severe immune complications. The elevated immune response of CD4 + T cells was reported in COVID-19 convalescent individuals [85]. B lymphocytes secreted an elevated level of IL-8 and reduced level of the anti-inflammatory factor like IL-10 in patients with T2DM [86]. In addition, the researchers reported that the altered activity of Toll-like receptors (TLR) in B lymphocytes was responsible for exaggerated inflammatory response. The elevated pro-inflammatory response from T and B lymphocyte among patients with diabetes may promote additional inflammation in COVID-19, often leading to lethal complications.

5. Possible therapeutic strategies to manage COVID-19 associated with DM

Hyperglycemia increases the severity of pathogenesis in COVID-19, resulting in several lethal complications and often fatality. However, some therapeutic agents have been suggested to manage the exacerbation of COVID-19 complication in patients with diabetes mellitus. Firstly, glucagon-like peptide-1 (GLP-1) receptor agonists which manage blood sugar level by provoking insulin secretion, reducing appetite, and decreasing plasma glucagon, have shown significant anti-diabetic and anti-inflammatory effects [87]. Moreover, inflammatory response and insulin resistance can also be lowered by reducing the macrophage infiltration in lesion site through the GLP-1 dependent M1/M2 macrophage polarization [88]. Secondly, dipeptidyl peptidase IV (DPP4) inhibitors resist the action of DPP4 which is expressed ubiquitously on the diverse tissues including immune cells [89] and degrades GLP-1 leading to impaired glucose metabolism. Beside the regulation of glucose metabolism, higher expression of DPP4 also promotes adipocyte inflammation and hepatic insulin resistance [89]. The administration of the soluble DPP4 has shown elevated secretion of pro-inflammatory mediators such as IL-6, IL-8 and MCP-1. The soluble DPP4 induces inflammation through nuclear factor (NF-κB) pathways, and the inflammation can be prevented inhibition of DPP4 [90]. Human DPP4 knock-in mice which were developed to understand the mechanism of interaction between DPP4 and coronavirus, facilitate the proliferation of MERS-CoV in the lung upon inoculation [91]. Therefore, DPP4 is promising target for alleviating chronic T2DM and inflammation. The use of DPP4 inhibitor blockade the activity of DPP4, and as a result the function of GLP-1 will restore for long time which may lead the better glycemic control in COVID-19 patients with DM. In a multicentre, retrospective clinical trial of hospitalized COVID-19 individuals with type 2 diabetes, sitagliptin, a highly selective DPP4 inhibitor, was treated to the patients for two months and the outcome was linked to lower fatality rate [92]. The findings were consistent with a single centred comparative study of COVID-19 patients affected by type 2 diabetes. The use of DPP inhibitor reduced the mortality rate whereas treatment of other antidiabetic drugs did not show such efficacy [93]. However, a few studies reported the neutral effect of DPP4 inhibitor. The treatment of DPP4 inhibitor prior to hospitalization did not improve the primary consequence of COVID-19 patients [94]. In another study, previous use of
DPP4 inhibitor neither reduce risk of hospitalization of COVID-19 patients nor improve the outcome of COVID-19 patients with diabetes when compared with SGLT inhibitors treatment [95]. However, an observational cohort study involving numerous individuals with type 2 diabetes reported a slightly higher risk of COVID-19 related mortality due to pre-prescribed DPP4 inhibitor therapy [96]. The limitation of the case-control studies is the small sample size. Therefore, large-size retrospective trials are recommended to conclude the efficacy of DPP4 inhibitor.

On the other hand, use of metformin, a popular hypoglycemic agent, provides promising outcome among the SARS-CoV-2 infected T2D patients in terms of survivability and resilience against hyperglycemia induced COVID-19 morbidity. In particular, metformin helps to alleviate diabetic condition by stimulating insulin responsiveness and metabolic control of glucose and lipid metabolism [97,98]. As per some clinical investigations conducted among T2D patients who were hospitalized following the diagnosis of COVID-19, it was reported that individuals who used to take metformin prior to get tested positive for novel corona virus showed less severity and mortality as compared to the non-metformin users [99,100]. The uninterrupted metformin therapy to the hospitalized patients with diabetes after they diagnosed with COVID-19, effectively promoted overall health and survivability [101]. However, some discrepancies exist among the available evidences where the efficacy profile of metformin in this regard remained unsatisfactory [102,103]. Supportive evidence has been found from a nationwide observational investigation in England. The study clearly demonstrated a statistically reduced risk of COVID-19-associated fatality in type 2 diabetic subjects who used metformin before SARS-CoV-2 infection [96]. In addition, other glucose-lowering medications like sulfonylureas and SGLT2 inhibitors showed lower risk of fatality. Two clinical examinations depicted the reduction of death risk only in female T2D patients but not in male as an outcome of metformin use [104,105]. Moreover, in depth molecular mechanism behind the ameliorating role of metformin in the prognosis of aggravated COVID-19 susceptibility in diabetic subjects is largely unknown and the existing study reports are found to be observational only. Furthermore, future studies are required to dissect the post COVID-19 complications if any among the metformin using survivor T2D patients.

As virus may alter the conformation of their surface proteins which are responsible for antigenicity, it is better to modulate host response to SARS-CoV-2. Thirdly, inhibitor for host serine protease like TMPRSS2 could be a good choice to curb the SARS-CoV-2 infection. Fourthly, administration of inhibitors of NF-κB like CAPE and parthenolide, caused higher expression of pro-inflammatory cytokines in lungs and eventually increased the survival rate of SARS-CoV infected mice [78]. Therefore, inhibitors of TMPRSS2 and NF-κB may be potential antivirals in SARS-CoV-2 treatment. Fifthly, the plasma samples of convalescent COVID-19 patients have seemingly shown encouraging result in SARS-CoV-2 infected individuals without any severe adverse effect [106]. Therefore, the convalescent plasma could be a potential boost for recovering COVID-19 patients [107]. However, the critical evaluation with control trial remains to be explored in large number of patients.

As both DM and COVID-19 exaggerate inflammatory markers in circulation of patients, the antidiabetic drugs which have anti-inflammatory property can be good players in this respect. One review has systematically elaborated the anti-inflammatory efficacy of a number of antidiabetic agents which can be used to reduce hyperactivated inflammatory response of SARS-CoV-2 infected patients [108]. Considering all, concrete validation is very much necessary in addressing particular drug to combat major challenges in COVID-19 infected diabetic patients.

Finally, some COVID-19 vaccines have shown promising results with satisfactory safety profile and considerable immune response. However, immunogenicity, safety, and efficacy of COVID-19 vaccines particularly to the patients with diabetes are needed to be optimised well.

6. Conclusion

Diabetes mellitus is one of the major comorbidities in COVID-19 patients. The pre-existing diabetes mellitus seems not to a risk factor for SARS-CoV-2 infection; however, the severity of COVID-19 pathogenesis and fatality cases are elevated due to the pre-existing uncontrolled diabetes mellitus. On the other hand, COVID-19 is associated with poor glycemic control in patients with DM. The serious pathophysiology of COVID-19 patients with DM is governed by a plethora biochemical factors including key peptides such as Ang II, cytokines, and other effector proteins which facilitate complex network pathways and eventually leads to lethal complications. As mentioned, DM is a multi-factorial metabolic disease which impairs the immune system in such a way that SARS-CoV-2 infection results in over activated and uncontrolled immune response. The cellular internalization of viral particles not only destructs the host cells but also aggravates the pro-inflammatory responses such as secretion of cytokines and chemokines in COVID-19 patients with DM. Thus, aggravation of COVID-19 pathophysiology is strongly associated with hyperactivation of immune system. The paucity of detail investigation on the interplay between DM and COVID-19 pathogenesis demands further studies to unveil the precise etiology underlying the heightened immune response in patients with diabetes.

CRediT authorship contribution statement

Sanjib Sarkar: Conceptualization, Writing - original draft, Writing - review & editing, Visualization. Dibyendu Das: Writing - review & editing. Sawlang Borsingh Wann: Supervision, Validation. Jatin Kalita: Supervision, Validation. Prasenjit Manna: Supervision, Writing - review & editing, Validation.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgement

The authors are thankful to the Director, CSIR-NEIST for his support, CSIR, Government of India, for providing the Senior Research Fellowship to Mr. Sanjib Sarkar (19/06/2016(ii)) EU-V dt 01-07-2017 & Sr. No. 1061630992) and Mr. Dibyendu Das (18/12/2016(iii)) EU-V dt 13-02-2017 & Sr. No. 1121631073), and DBT, Government of India, for providing the Ramalingaswami Re-Entry Fellowship Grant to Dr. Manna (BT/RE/Re-Entry/34/2013).

REFERENCES

[1] Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276–8.
[2] Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2003;305:676–9.
[3] Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814–20.
[4] Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.
[5] Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265–9.
[6] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727–33.
[7] Morawska L, Milton DK. It is Time to Address Airborne Transmission of COVID-19. Clin Infect Dis 2020.
[8] World Health Organization. Coronavirus Disease (COVID-19) Situations Reports. (World Health Organization 2020).
[9] Ma RCW, Holt RIG. COVID-19 and diabetes. Diabet Med 2020;37:723–5.
[10] Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003;26:510–3.
[11] Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005;41:281–8.
[12] Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in Patients with Diabetes Mellitus. N Engl J Med 1999;341:1906–12.
[13] Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology 2015;144:171–85.
[14] Yang JK, Fung Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23:623–8.
[15] Banik GR, Alqahtani AS, Booy R, Rashid H. Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. Virol Sin 2016;31:81–4.
[16] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
[17] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020.
[18] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Italy. JAMA. 2020;323:1574–81.
[19] Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020;43:867–9.
[20] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan China. JAMA 2020;323:1061–9.
[21] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020.
[22] Wu C, Chen X, Cai Y, Ja Xia, Zhou X, Xu S, et al. Pneumonia in Wuhan, China. JAMA. Intern Med 2019;2020:e200994.
[23] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020;5(7):1–8.
[24] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J 2020;2000547.
[25] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet 2020;395:497–506.
[26] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet. Respir Med. 2020.
[27] Seiglie J, Platt J, Cromer SJ, Bunda B, Foulaikel AS, Bassett IV, et al. Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized With COVID-19. Diabetes Care 2020;43:2938–44.
[28] Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy JAMA 2020;323:1775–6.
[29] Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center. Retrospective Study. Diabetes Care 2020;43:1382–91.
[30] Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell LF, Chernyak Y, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv. 2020-2020.04.08.20057794.
[31] Zhu L, She ZZ, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 2020;31:1068 77.e3.
[32] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020;323:2052–9.
[33] Kim MK, Jeon JH. The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu. South Korea. Diabetes Metab J 2020;44:602–13.
[34] Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020;92:797–806.
[35] Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. N Engl J Med 2020;382:2534–43.

[36] Dennis JM, Mateen BA, Sonabend R, Thomas NJ, Patel KA, Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes Lopes RD, Macedo AVS, de Barros ESPGM, Moll-Bernardes RJ, Fignani D, Licata G, Brusco N, Nigi L, Grieco GE, Marselli L, Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med 2021;9:275–94.

[37] Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. JAMA 2020;323:2195–8.

[38] Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020.

[39] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181(271–80) e8.

[40] Zhou L, Niu Z, Jiang X, Zhang Z, Zheng Y, Wang Z, et al. Systemic analysis of tissue cells potentially vulnerable to SARS-CoV-2 infection by the protein-proofed single-cell RNA profiling of ACE2, TMPRSS2 and Furin proteases. bioRxiv. 2020;2020.06.028522.

[41] Sungnak W, Hyung N, Bécam-V, Berg R, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020;26:681–7.

[42] Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020;12:8.

[43] Battle D, Jose Soler M, Ye M. ACE2 and diabetes: ACE of ACE2s?. Diabetes 2010;59:2994–6.

[44] Patel VB, Parajuli N, Oudit GY. Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. Clin Sci (Lond) 2014;126:471–82.

[45] Mizuiri S, Hemmi H, Arita M, Ohashi Y, Tanaka Y, Miyagi M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008;51:613–23.

[46] Pal R, Bhanasai A. COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res Clin Pract 2020;162 108132.

[47] Wijnant SRA, Jacobs M, Van Eeckhoutte HP, Lapauw B, Joos GF, Bracke KR, et al. Expression of ACE2, the SARS-CoV-2 Receptor, in Lung Tissue of Patients With Type 2 Diabetes. Diabetes 2020;69:2691–9.

[48] Ferrario CM, Jessup J, Chappell MC, Averill DB, Bronsibn KB, Tallant EA, et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. Circulation 2005;111:2605–10.

[49] Sukumaran V, Tsuchimochi H, Tatsumi E, Shirai M, Machado JA. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis 2018;9:119.

[50] Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond) 2012;123:649–58.

[51] Fang L, Karakulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med 2020;8 e21.

[52] Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020;382:2441–8.

[53] Mancia G, Rea F. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. 2020;382:2431–40.

[54] Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020.

[55] Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med 2021;9:275–94.

[56] Lopes RD, Macedo AVS, de Barros ESPGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA 2021;325:254–64.

[57] Fignani D, Licata G, Brusco N, Nigli GP, Grieco GE, Marselli L, et al. SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic β-Cells and in the Human Pancreas Microvasculature. Front Endocrinol 2020;11.

[58] Kusmartseva I, Wu W, Syed F, Van Der Heide V, Jorgensen M, Joseph P, et al. Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19. Cell Metab 2020;32:1041–51.

[59] Gao W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020:e3319.

[60] Wu L, Girgis CM, Cheung NW. COVID-19 and diabetes: Insulin requirements parallel illness severity in critically unwell patients. Clin Endocrinol 2020;93:390–3.

[61] Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98–107.

[62] Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008;31 (Suppl 2):S161–4.

[63] Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 2010;11:987–904.

[64] Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020.

[65] Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, Nogueira-Machado JA. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis 2018;9:119.

[66] Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hyperglycosemia. Diabetes 1994;43:1122–9.

[67] Yang JHM, Giacca A. Role of e-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes. Cell 2020;9.
Huang R, Xi J, Yang B, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.

Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323(18):1972–3.

Poon L, Yip W, Yuen K-M. Coronavirus infection in 2020: an update. J Antimicrob Chemother 2020;75(4):889–907.

Wu ZQ, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese center for disease control and prevention. JAMA 2020;323(18):1972–3.

Huang C, Wang Y, Li X, et al. Clinical features of 99 Italian patients with COVID-19. Intensive Care Med 2020;46(5):804–10.

Lan Y, Xu Y, Gao L, et al. Transmission of 2019 novel coronavirus (COVID-19) infection from an asymptomatic mother to her infant. Lancet Infect Dis 2020;20(5):565–6.
Metformin and Risk of Mortality in Patients Hospitalized with Covid-19. medRxiv. 2020:2020.06.19.20135095.

Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, et al. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Healthy longevity. 2021;2:e34–41.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv. 2020:2020.03.16.20036145.

Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20:398–400.

Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?. J Diabetes Complicats. 2020;34 107723.